Mineral and bone disorders in children with chronic kidney disease

Nature Reviews Nephrology

Volumn 7, Issue 11, 2011, Pages 624-634

  Schmitt, Claus Peter ^a   Mehls, Otto ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CINACALCET; COLECALCIFEROL; DOXERCALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; MINERAL; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; PROCOLLAGEN; SEVELAMER CARBONATE; TELOPEPTIDE;

AGE DISTRIBUTION; BONE BIOPSY; BONE DISEASE; BONE RADIOGRAPHY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHILD; CHILD GROWTH; CHRONIC KIDNEY DISEASE; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; HEMODIAFILTRATION; HOMEOSTASIS; HORMONE DETERMINATION; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; MINERAL AND BONE DISORDE; MINERAL AND BONE DISORDER; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PATIENT MONITORING; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PUBERTY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL OSTEODYSTROPHY; REVIEW; RICKETS; UREMIA; VITAMIN SUPPLEMENTATION;

CHILD; HOMEOSTASIS; HUMANS; MINERALS; NAPHTHALENES; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY;

EID: 80255139971     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.139     Document Type: Review

References (127)

1. Moe, S. et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 69, 1945-1953 (2006).
2. Borzych, D. et al. The bone and mineral disorder of children undergoing chronic peritoneal dialysis. Kidney Int. 78, 1295-1304 (2010).
3. Oh, J. et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106, 100-105 (2002).
4. Goodman, W. G. et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 342, 1478-1483 (2000).
5. McDonald, S. P. & Craig, J. C. Long-term survival of children with end-stage renal disease. N. Engl. J. Med. 350, 2654-2662 (2004).
6. Shroff, R. et al. Vitamin D deficiency is associated with short stature and may influence blood pressure control in paediatric renal transplant recipients. Pediatr. Nephrol. http://dx.doi.org/10.1007/s00467-011-1920-z.
7. Gwinner, W. et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am. J. Transplant. 5, 1934-1941 (2005).
8. Ramirez, J. A. et al. The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int. 30, 753-759 (1986).
9. Bushinsky, D. A. Contribution of intestine, bone, kidney, and dialysis to extracellular fluid calcium content. Clin. J. Am. Soc. Nephrol. 5 (Suppl. 1), S12-S22 (2010).
10. Soldin, S. J., Brugnara, C. & Wong, E. C. (eds) Pediatric reference ranges (AACC-Press, Washington, 2003).
11. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Nutrition in Children with CKD: 2008 Update. Am. J. Kidney Dis. 53 (Suppl. 2), S1-S124 (2009).
12. Brodehl, J. Assessment and interpretation of the tubular threshold for phosphate in infants and children. Pediatr. Nephrol. 8, 645 (1994).
13. Clayton, B. E., Jenkins, P. & Round, J. M. (eds) Paediatric chemical pathology: clinical tests and references ranges (Blackwell Scientific, Oxford 1980).
14. Sitzmann, F. C. in Pädiatrie (ed. Sitzmann, F. C.), 193 (Hippokrates Verlag, Stuttgart, 1995).
15. Häusler, M., Schäfer, C., Osterwinter, C. & Jahnen-Dechent, W. The physiologic development of fetuin a serum concentrations in children. Pediatr. Res. 66, 660-664 (2009).
16. Wigger, M. et al. Fetuin A serum concentrations in healthy children. Ann. Clin. Biochem. 46, 511-513 (2009).
17. Picca, S. et al. Parathyroid hormone levels in pubertal uremic adolescents treated with growth hormone. Pediatr. Nephrol. 19, 71-76 (2004).
18. Bhan, I. et al. Post-transplant hypophosphatemia: tertiary 'hyper-phosphatoninism'? Kidney Int. 70, 1486-1494 (2006).
19. Klaus, G. et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr. Nephrol. 21, 151-159 (2006).
20. Salusky, I. B. et al. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int. 45, 253-258 (1994).
21. Gal-Moscovici, A. & Popovtzer, M. M. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin. Nephrol. 63, 284-289 (2005).
22. John, M. R. et al. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J. Clin. Endocrinol. Metab. 84, 4287-4290 (1999).
23. Salusky I. B.et al., Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int., 63, 1801-1808 (2003
24. Wesseling-Perry, K. et al. Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. Pediatr. Nephrol. 24, 1355-1361 (2009).
25. Slatopolsky, E. et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 58, 753-761 (2000).
26. Waller, S. C., Ridout, D., Cantor, T. & Rees, L. Parathyroid hormone and growth in children with chronic renal failure. Kidney Int. 67, 2338-2345 (2005).
27. Cantor, T., Yang, Z., Caraiani, N. & Ilamathi, E. Lack of comparability of intact parathyroid hormone measurements among commercal assays for end-stage renal disease patients: implication for treatment decisions. Clin. Chem. 52, 1771-1776 (2006).
28. Gardham, C. et al. Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin. J. Am. Soc. Nephrol. 5, 1261-1267 (2010).
29. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 113, S1-S130 (2009).
30. National Kidney Foundation. K/DOQI Clinical Practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am. J. Kidney Dis. 46 (Suppl. 1), 1-122 2005).
31. Kuizon, B. D. et al. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int. 53, 205-211 (1998).
32. Schmitt, C. P Ardissino, G., Testa, S., Claris-Appiani, A. & Mehls, O. Growth in children with chronic renal failure on intermittent versus daily calcitriol. Pediatr. Nephrol. 18, 440-444 (2003).
33. Waller, S. C., Ridout, D., Cantor, T. & Rees, L. Parathyroid hormone and growth in children with chronic renal failure. Kidney Int. 67, 2338-2345 (2005).
34. Waller, S., Shroff, R., Freemont, A. J. & Rees, L. Bone histomorphometry in children prior to commencing renal replacement therapy. Pediatr. Nephrol. 23, 1523-1529 (2008).
35. Cansick, J., Waller, S., Ridout, D. & Rees, L. Growth and PTH in prepubertal children on long-term dialysis. Pediatr. Nephrol. 22, 1349-1354 (2007).
36. Fischbach, M. et al. Daily on line haemodiafiltration promotes catch-up growth in children on chronic dialysis. Nephrol. Dial. Transplant. 25, 867-73 (2010)
37. Salusky, I. B. et al. Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int. 54, 907-914 (1998).
38. Bakkaloglu, S. A. et al. Value of the new bone classification system in pediatric renal osteodystrophy. Clin. J. Am. Soc. Nephrol. 5, 1860-866 (2010).
39. Salusky, I. B. et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J. Am Soc. Nephrol. 16, 2501-2508 (2005).
40. Piscitelli, J., Cabansag, M. R. & Silverstein, D. M. Correlation among markers of renal osteodystrophy in pediatric hemodialysis patients. J. Pediatr. Endocrinol Metab. 12, 879-886 (1999).
41. Christoforidis, A. et al. Comparative study of quantitative ultrasonography and dual-energy X ray absorptiometry for evaluating renal osteodystrophy in children with chronic kidney disease. J. Bone Miner. Metab. 29, 321-327 (2011).
42. Siomou, E. et al. Serum osteoprotegerin, RANKL and fibroblast growth factor 23 in children with chronic kidney disease. Pediatr. Nephrol. 26, 1105-1114 (2011).
43. Ziólkowska, H. et al. Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatr. 89, 666-671 (2000).
44. Fahrleitner-Pammer, A. et al. Bone markers predict cardiovascular events in chronic kidney disease. J. Bone Miner. Res. 23, 1850-1858 (2008).
45. Baber, U. et al. Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort. Kidney Int. 73, 615-621 (2008).
46. Mohandas, R. & Segal, M. S. Endothelial progenitor cells and endothelial vesicles-what is the significance for patients with chronic kidney disease. Blood Purif. 29, 158-162 (2010).
47. Bacchetta, J. et al. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J. Clin. Endocrinol. Metab. 95, 1741-1748 (2010).
48. van Husen, M. et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int. 78, 200-206 (2010).
49. Isakova, T. et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79, 1370-1378 (2011).
50. Petkovich, M. & Jones, G. CYP24A1 and kidney disease. Curr. Opin. Nephrol. Hypertens. 20, 337-344 (2011).
51. Wesseling-Perry, K. et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor 23 in secondary hyperparathyroidism. Kidney Int. 79, 112-119 (2011).
52. Larsson, T., Nisbeth, U., Ljunggren, O., Jüppner, H. & Jonsson, K. B. Circulating concentration of FGF 23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 64, 2272-2279 (2003).
53. Gutiérrez, O. M. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359, 584-592 (2008).
54. Wolf, M. et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J. Am. Soc. Nephrol. 22, 956-966 (2011).
55. Gutiérrez, O. M. et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119, 2545-2552 (2009).
56. Kanbay, M. et al. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin. J. Am. Soc. Nephrol. 5, 1780-1786 (2010).
57. Manghat, P. et al. Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD). Bone 48, 1127-1132 (2011).
58. Wesseling-Perry, K., Tsai, E. W., Ettenger, R. B., Jüppner, H. & Salusky, I. B. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF 23? Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/gfr126.
59. Wesseling-Perry, K. et al. Relationship between plasma fibroblast growth factor 23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J. Clin. Endocrinol. Metab. 94, 511-517 (2009).
60. Russo, D. & Battaglia, Y. Clinical significance of FGF 23 in patients with CKD. Int. J. Nephrol. 2011, 364890 (2011).
61. Schönau, E. The peak bone mass concept: is it still relevant? Pediatr. Nephrol. 19, 825-831 (2004).
62. Weber, L. T. & Mehls, O. Limitations of dual x ray absorptiometry in children with chronic kidney disease. Pediatr. Nephrol. 25, 3-5 (2010).
63. Bacchetta, J. et al. Bone assessment in children with chronic kidney disease: data from two new bone imaging techniques in a single-center pilot study. Pediatr. Nephrol. 26, 587-595 (2011).
64. Leonard, M. B. et al. Effects of sex, race, and puberty on cortical bone and the functional muscle bone unit in children, adolescents, and young adults. J. Clin. Endocrinol. Metab. 95, 1681-1689 (2010).
65. Ziólkowska, H. et al. Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatr. 89, 666-671 (2000).
66. Salusky, I. B. et al. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int. 45, 253-258 (1994).
67. Glorieux, F. H. et al. Normative data for iliac bone histomorphometry in growing children. Bone 26, 103-109 (2000).
68. LaClair, R. E. et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am. J. Kidney Dis. 45, 1026-1033 (2005).
69. Hari, P. et al. Vitamin D insufficiency and effect of cholecalciferol in children with chronic kidney disease. Pediatr. Nephrol. 25, 2483-2488 (2010).
70. Ali, F. N., Arguelles, L. M., Langman, C. B. & Price, H. E. Vitamin D deficiency in children with chronic kidney disease: uncovering an epidemic. Pediatrics 123, 791-796 (2009).
71. Shroff, R. et al. Vitamin D deficiency is associated with short stature and may influence blood pressure control in paediatric renal transplant recipients. Pediatr. Nephrol. http://dx.doi.org/10.1007/s00467-011-1920-z.
72. Holick, M. F. Vitamin D deficiency. N. Engl. J. Med. 357, 266-281 (2007).
73. Matias, P. J. et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin. J. Am. Soc. Nephrol. 5, 905-911 (2010).
74. Menon, S., Valentini, R. P., Hidalgo, G., Peschansky, L. & Mattoo, T. K. Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease. Pediatr. Nephrol. 23, 1831-1836 (2008).
75. Shroff, R. et al. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J. Am. Soc. Nephrol. 19, 1239-1246 (2008).
76. Jones, G. Pharmacokinetics of vitamin D toxicity. Am. J. Clin. Nutr. 88, 582S-586S (2008).
77. Teng, M. et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 349, 446-456 (2003).
78. Tentori, F. et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 70, 1858-1865 (2006).
79. Nuijten, M., Andress, D. L., Marx, S. E., Curry, A. S. & Sterz, R. Cost effectiveness of paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model. Clin. Drug Investig. 30, 545-557 (2010).
80. Sprague, S. M., Llach, F., Amdahl, M., Taccetta, C. & Batlle, D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 63, 1483-1490 (2003).
81. Llach, F. et al. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19 nor 1,25- dihydroxyvitamin D2. Am. J. Kidney Dis. 32 (2 Suppl. 2), S48-S54 (1998).
82. Palmer, S. C. et al. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database of Systematic Reviews Issue 7. Art. No.: CD005633. doi:10.1002/14651858.CD005633.pub2 (2009)
83. Palmer, S. C.et al. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews Issue 7 Art. No.: CD008175 doi:10.1002/14651858.CD008175 (2009).
84. Finch J. L. Brown A. J. Slatopolsky, E. Differential effects of 1,25 dihydroxy vitamin D3 and 19 nor 1,25 dihydroxy vitamin D2 on calcium and phosphorus resorption in bone. J. Am. Soc. Nephrol. 10, 980-985 (1999)
85. Brown, A. J., Finch, J. & Slatopolsky, E. Differential effects of 19 nor 1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J. Lab. Clin. Med. 139, 279-284 (2002).
86. Mizobuchi, M., Finch, J. L., Martin, D. R. & Slatopolsky, E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. 72, 709-715 (2007).
87. Becker, L. E. et al. Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice. Am. J. Physiol. Renal Physiol. 300, F772-F782 (2011).
88. Repo, J. M. et al. Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. Kidney Int. 72, 977-984 (2007).
89. Greenbaum, L. A. et al. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am. J. Kidney Dis. 49, 814-823 (2007).
90. Seeherunvong, W. et al. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr. Nephrol. 21, 1434-1439 (2006).
91. Tsuruoka, S., Wakaumi, M., Sugimoto, K., Saito, T. & Fujimura, A. Chronotherapy of high-dose active vitamin D3 in haemodialysis patients with secondary hyperparathyroidsm: a repeated dosing study. Br. J. Clin. Pharmacol. 55, 531-537 (2003).
92. Pieper, A. K. et al. A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. Am. J. Kidney Dis. 47, 625-635 (2006).
93. Gonzalez, E., Schomberg, J., Amin, N., Salusky, I. B. & Zaritsky, J. Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients. Pediatr. Nephrol. 25, 373-375 (2010).
94. Chertow, G. M., Burke, S. K. & Raggi, P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 62, 245-252 (2002).
95. Kakuta, T. et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am. J. Kidney Dis. 57, 422-431 (2011).
96. Block, G. A., Raggi, P., Bellasi, A., Kooienga, L. & Spiegel, D. M. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 71, 438-441 (2007).
97. Navaneethan, S. D., Palmer, S. C., Craig, J. C., Elder, G. J. & Strippoli, G. F. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am. J. Kidney Dis. 54, 619-637 (2009).
98. Hutchison, A. J., Barnett, M. E., Krause, R. J. & Siami, G. A. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease stage 5 receiving hemodialysis. Clin. Nephrol. 71, 286-295 (2009).
99. Lacour, B. et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. 67, 1062-1069 (2005).
100. Davis, R. L. & Abraham, J. L. Lanthanum deposition in a dialysis patient. Nephrol. Dial. Transplant. 24, 3247-3250 (2009).
101. Spasovski, G. B. et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol. Dial. Transplant. 21, 2217-2224 (2006).
102. Strippoli, G. F., Tong, A., Palmer, S. C., Elder, G. & Craig, J. C. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database of Systematic Reviews Issue 18 Art. No.: CD006254 doi:10.1002/14651858.CD006254 (2006).
103. Meola, M., Petrucci, I. & Barsotti, G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol. Dial. Transplant. 24, 982-989 (2009).
104. Raggi, P. et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular alcification in patients on hemodialysis. Nephrol. Dial. Transplant. 26, 1327-1339 (2011).
105. Muscheites, J. et al. Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr. Nephrol. 23, 1823-1829 (2008).
106. Silverstein, D. M. et al. Cinacalcet is efficacious in pediatric dialysis patients. Pediatr. Nephrol. 23, 1817-1822 (2008).
107. Bacchetta, J. et al. Precocious puberty and unlicensed paediatric drugs for severe hyperparathyroidism. Nephrol. Dial. Transplant. 24, 2595-2598 (2009).
108. European Medicines Agency European Assessment Report MIMPARA [online], www.ema.europa.eu (2009).
109. Wu, S., Palese, T., Mishra, O. P., Delivoria-Papadopoulos, M. & De Luca, F. Effects of Ca2+ sensing receptor activation in the growth plate. FASEB J. 18, 143-145 (2004).
110. Rodriguez, L., Cheng, Z., Chen, T. H., Tu, C. & Chang, W. Extracellular calcium and parathyroid hormone-related peptide signaling modulate thepace of growth plate chondrocyte differentiation. Endocrinology 146, 4597-4608 (2005).
111. Schmitt, C. P. et al. Intermittent administration of parathyroid hormone (1-37) improves growth and bone mineral density in uremic rats. Kidney Int. 57, 1484-1492 (2000).
112. Lee, K. et al. Parathyroid hormone-related peptide delays terminal differentiation of chondrocytes during endochondral bone development. Endocrinology 137, 5109-5118 (1996).
113. Lanske, B. et al. PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273, 663-666 (1996).
114. Garner, S. C., Pi, M., Tu, Q. & Quarles, L. D. Rickets in cation-sensing receptor-deficient mice: an unexpected skeletal phenotype. Endocrinology 142, 3996-4005 (2001).
115. Kos, C. H. et al. The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J. Clin. Invest. 111, 1021-1028 (2003).
116. Tu, Q. et al. Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. J. Clin. Invest. 111, 1029-1037 (2003).
117. Mittelman, S. D. et al. A hypocalcemic child with a novel activating mutation of the calcium-sensing receptor gene: successful treatment with recombinant human parathyroid hormone. J. Clin. Endocrinol. Metab. 91, 2474-2479 (2006).
118. Burren, C. P., Curley, A., Christie, P., Rodda, C. P. & Thakker, R. V. A family with autosomal dominant hypocalcaemia with hypercalciuria (ADHH): mutational analysis, phenotypic variability and treatment challenges. J. Pediatr. Endocrinol. Metab. 18, 689-699 (2005).
119. Uckun-Kitapci, A., Underwood, L. E., Zhang, J. & Moats-Staats, B. A novel mutation (E767K) in the second extracellular loop of the calcium sensing receptor in a family with autosomal dominant hypocalcemia. Am. J. Med. Genet. 132, 125-129 (2005).
120. Nakagawa, K. et al. Cinacalcet does not affect longitudinal growth but increases body weight gain in experimental uraemia. Nephrol. Dial. Transplant. 23, 2761-2767 (2008).
121. Platt, C. et al. Middle-term use of cinacalcet in paediatric dialysis patients. Pediatr. Nephrol. 25, 143-148 (2010).
122. DrugLib.com Well-designed clinical trials related to Sensipar (cinacalcet) [online], www.druglib.com/druginfo/sensipar/abstracts/ (2011).
123. Henley, C. 3rd et al. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion. J. Pharmacol. Exp. Ther. 337, 681-691 (2011).
124. Oh, J. et al. Stimulation of the calcium-sensing receptor stabilizes the podocyte cytoskeleton, improves cell survival, and reduces toxin-induced glomerulosclerosis. Kidney Int. 80, 483-492 (2011).
125. Finch, J. L. et al. Effect of paricalcitol and cinacalcet on serum phosphate, FGF 23, and bone in rats with chronic kidney disease. Am. J. Physiol. Renal Physiol. 298, F1315-F1322 (2010).
126. Cunningham, J., Locatelli, F. & Rodriguez, M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin. J. Am. Soc. Nephrol. 6, 913-921 (2011).
127. Schaefer, B. et al. Long-term control of parathyroid hormone and calcium-phosphate metabolism after parathyroidectomy in children with chronic kidney disease. Nephrol. Dial. Transplant. 25, 2590-2595 (2010).